Overview

  • Product name

    SB 939,  HDAC inhibitor
  • Description

    Potent HDAC inhibitor
  • Biological description

    Potent HDAC inhibitor (IC50 = 77 nM, HDAC1). Shows antiproliferative effects in cancer cell lines (IC50 values are 480, 560, 480, and 340 nM for A2780, COLO 205 and HCT-116 and PC-3 lines respectively). Shows antitumor and potent antimalarial effects in vivo. Orally active.
  • Purity

    > 98%
  • CAS Number

    929016-96-6
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    (E)-3-[2-Butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide
  • Molecular weight

    358.48
  • Molecular formula

    C20H30N4O2
  • PubChem identifier

    49855250
  • Storage instructions

    Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in ethanol to 10 mM and in DMSO to 75 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO
  • Source

    Synthetic

  • Research areas

References

This product has been referenced in:

  • Okabe S  et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int 13:32 (2013). Read more (PubMed: 23556431) »
  • Sumanadasa SD  et al. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother 56:3849-56 (2012). Read more (PubMed: 22508312) »
  • Novotny-Diermayr V  et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2:e69 (2012). Read more (PubMed: 22829971) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab144404.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up